Fengmin Shao

机构：Heidelberg University, University Hospital Heidelberg, Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou Central Hospital, Zhengzhou People's Hospital · ORCID：0000-0003-2905-4312

发表论文 77 篇 · 总被引 1511 次 · h-index 18

代表论文

• Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (2023 · The Lancet Diabetes & Endocrinology · 被引 117)
• Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (2023 · The Lancet Diabetes & Endocrinology · 被引 94)
• C-kit controls blood-brain barrier permeability by regulating caveolae-mediated transcytosis after chronic cerebral hypoperfusion (2023 · Biomedicine & Pharmacotherapy · 被引 13)
• Renal-clearable and mitochondria-targeted metal-engineered carbon dot nanozymes for regulating mitochondrial oxidative stress in acute kidney injury (2025 · Materials Today Bio · 被引 11)
• Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury (2024 · Renal Failure · 被引 10)
• Receptor-interacting protein kinase 1 confers autophagic promotion of gasdermin E-mediated pyroptosis in aristolochic acid-induced acute kidney injury (2024 · Ecotoxicology and Environmental Safety · 被引 9)